Traffic:
10E
10W
15N
15S
57N
57S
60E
60W
210E
210W
This Site
Web Search
powered by
YAHOO! SEARCH
Subscriber Services
|
Home Delivery
|
e-Edition
|
Alerts
|
RSS
Home
News
Ontario
Rancho Cucamonga
Pomona
Upland
Claremont
Montclair
Chino Valley
California
Crime & Public Safety
Elections
Education
S.B. County Watch
Upland Watch
I.E.: Medicare Testing Ground
Sports
Buy Event Tickets Now
Golf - Tee Times and Courses
Preps
Reign Hockey
Rancho Cucamonga Quakes
Local Colleges
USC
UCLA
Lakers
Clippers
Dodgers
Angels
Ducks
Soccer
Motor Sports
Horse Racing
Live Odds
Business
Autos
Real Estate News
Technology
Opinions
Editorial
Letters
Columnists
Blogs
LA.COM
Buy Tickets
Movies
TV
Music
Shopping & Beauty
Recreation
Neighborhood
Arts
Living
Dining
Find A Restaurant
Lottery
Horoscopes
Travel
Trevor's Travels
Health
Crossword Puzzle
Local Casinos
Foothills Magazine
Info
Subscribe For Home Delivery
Contact Us
RSS
Podcast
Subscriber Services
Place An Ad
NIE
Classified
Place an Ad
Homes
Jobs
Auto
Search autos
Buy/Sell a car
Research/Financing a car
Find a dealer
Shopping
This week's ads
Obits
Directories
Local Business
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Acadia Pharmaceuticals Inc.
< Previous
1
2
3
Next >
Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024
October 17, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome
October 16, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 08, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 26, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals
September 23, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
August 28, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Ryan Reynolds Announces More to Parkinson’s® Campaign
August 14, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 44th Annual Growth Conference
August 07, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview
August 06, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024
July 24, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Clinical Data from Open-Label Extension LILAC-1™ and LILAC-2™ Studies Evaluating Long-Term Safety and Efficacy of DAYBUE™ (trofinetide) in Patients with Rett Syndrome Published in Med
July 18, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 17, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome
May 15, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
May 09, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview
May 08, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship
April 29, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024
April 24, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
April 22, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 19, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting
April 17, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development
April 02, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
April 01, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 15, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day
March 13, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia
March 11, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference on March 6, 2024
February 29, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operating Overview
February 27, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 21, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
February 13, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
Acadia Announces Additions to Executive Team
January 30, 2024
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Tickers
ACAD
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Privacy Policy
|
Terms of Use
|
MNG Corporate Site Map
|
Copyright